No abstract available
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage
-
Bortezomib
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase I as Topic
-
Disease Progression
-
Doxorubicin / administration & dosage
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Intracellular Signaling Peptides and Proteins / drug effects*
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Middle Aged
-
Perivascular Epithelioid Cell Neoplasms / drug therapy*
-
Perivascular Epithelioid Cell Neoplasms / secondary
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Serine-Threonine Kinases / drug effects*
-
Protein Serine-Threonine Kinases / metabolism
-
Pyrazines / administration & dosage
-
Retroperitoneal Neoplasms / drug therapy*
-
Retroperitoneal Neoplasms / secondary
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives*
-
TOR Serine-Threonine Kinases
-
Topotecan / administration & dosage
-
Treatment Failure
Substances
-
Boronic Acids
-
Intracellular Signaling Peptides and Proteins
-
Protein Kinase Inhibitors
-
Pyrazines
-
temsirolimus
-
Bortezomib
-
Topotecan
-
Doxorubicin
-
MTOR protein, human
-
Protein Serine-Threonine Kinases
-
TOR Serine-Threonine Kinases
-
Sirolimus